The introduction of immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein-1 (PD-1) or programmed death protein ligand-1 (PD-L1) have greatly changed the treatments of non-small cell lung cancer (NSCLC), malignant melanoma, and renal and other cancers. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.